The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Alnylam; Syros Pharmaceuticals
Stock and Other Ownership Interests - Alnylam; Biogen; Syros Pharmaceuticals
First-in-human phase I study of SY-5609, an oral, potent, and selective noncovalent CDK7 inhibitor, in adult patients with select advanced solid tumors.
 
Kyriakos P. Papadopoulos
Consulting or Advisory Role - ArQule; Bayer
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); ArQule (Inst); Bayer (Inst); Calithera Biosciences (Inst); Curegenix (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Formation Biologics (Inst); Incyte (Inst); Jounce Therapeutics (Inst); MabSpace Biosciences (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); OncoMed (Inst); Peloton Therapeutics (Inst); Regeneron (Inst); Sanofi (Inst); Syros Pharmaceuticals (Inst)
 
Manish Sharma
Research Funding - Alexo Therapeutics (Inst); Amgen (Inst); Apexian Pharmaceuticals (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Constellation Pharmaceuticals (Inst); Coordination Pharmaceuticals (Inst); CytomX Therapeutics (Inst); Exelixis (Inst); Formation Biologics (Inst); Forty Seven (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Innovent Biologics (Inst); Jounce Therapeutics (Inst); KLUS Pharma (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Northern Biologics (Inst); Pfizer (Inst); Regeneron (Inst); Symphogen (Inst); Syros Pharmaceuticals (Inst); TaiRx, Inc. (Inst); Tesaro (Inst)
 
Erika Paige Hamilton
Consulting or Advisory Role - AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Mersana (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Silverback Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Aravive (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); BerGenBio (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Compugen (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunomedics (Inst); InventisBio (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Novartis (Inst); Nucana (Inst); OncoMed (Inst); Orinove (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Regeneron (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutter Medical Group (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Torque (Inst); Torque (Inst); Unum Therapeutics (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; EMD Serono; Foundation Medicine; Genentech; Genentech/Roche; Genzyme; Guardant Health; Helsinn Therapeutics; HERON; Lexicon; Lilly; Lilly; Medivation; Merck; Novartis; Pfizer; Roche; Sysmex; Tesaro
 
Debra L. Richardson
Consulting or Advisory Role - AstraZeneca; Bayer; Foundation Medicine; Genentech/Roche; Ipsen; Mersana; Tesaro
Research Funding - Aravive (Inst); ArQule (Inst); AstraZeneca (Inst); Deciphera (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Harpoon therapeutics (Inst); Hookipa Biotech (Inst); Innovent Biologics (Inst); Karyopharm Therapeutics (Inst); Lycera (Inst); Merck (Inst); Mersana (Inst); Roche (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Agenus; Karyopharm Therapeutics; Merck; Roche; Tesaro
 
Graeme Hodgson
Employment - Syros Pharmaceuticals
Stock and Other Ownership Interests - Syros Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Syros Pharmaceuticals
 
Li Zhou
Employment - Incyte; Syros Pharmaceuticals; Teclison (I)
Stock and Other Ownership Interests - Incyte; Nektar; Syros Pharmaceuticals
 
Angela Volkert
Employment - Syros Pharmaceuticals
Stock and Other Ownership Interests - Syros Pharmaceuticals
 
Hina A. Jolin
Employment - Syros Pharmaceuticals
Stock and Other Ownership Interests - Syros Pharmaceuticals
 
Catherine Madigan
No Relationships to Disclose
 
Michael Kelly
Employment - Syros Pharmaceuticals
Stock and Other Ownership Interests - Syros Pharmaceuticals
 
David A. Roth
Employment - Syros Pharmaceuticals
Leadership - Syros Pharmaceuticals
Stock and Other Ownership Interests - Infinity Pharmaceuticals; Syros Pharmaceuticals